- Home
- LPTX vs CANF Comparison
LPTX vs CANF Comparison
Compare LPTX & CANF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LPTX
- CANF
- Stock Information
- Founded
- LPTX 2011
- CANF 1994
- Country
- LPTX United States
- CANF Israel
- Employees
- LPTX N/A
- CANF N/A
- Industry
- LPTX Biotechnology: Biological Products (No Diagnostic Substances)
- CANF Biotechnology: Pharmaceutical Preparations
- Sector
- LPTX Health Care
- CANF Health Care
- Exchange
- LPTX Nasdaq
- CANF Nasdaq
- Market Cap
- LPTX 14.7M
- CANF 13.5M
- IPO Year
- LPTX N/A
- CANF N/A
- Fundamental
- Price
- LPTX $0.35
- CANF $1.03
- Analyst Decision
- LPTX Hold
- CANF Strong Buy
- Analyst Count
- LPTX 1
- CANF 2
- Target Price
- LPTX N/A
- CANF $14.00
- AVG Volume (30 Days)
- LPTX 3.3M
- CANF 83.3K
- Earning Date
- LPTX 08-11-2025
- CANF 08-29-2025
- Dividend Yield
- LPTX N/A
- CANF N/A
- EPS Growth
- LPTX N/A
- CANF N/A
- EPS
- LPTX N/A
- CANF N/A
- Revenue
- LPTX N/A
- CANF $674,000.00
- Revenue This Year
- LPTX N/A
- CANF $461.72
- Revenue Next Year
- LPTX N/A
- CANF N/A
- P/E Ratio
- LPTX N/A
- CANF N/A
- Revenue Growth
- LPTX N/A
- CANF N/A
- 52 Week Low
- LPTX $0.22
- CANF $0.98
- 52 Week High
- LPTX $4.79
- CANF $4.69
- Technical
- Relative Strength Index (RSI)
- LPTX 52.39
- CANF 42.43
- Support Level
- LPTX $0.32
- CANF $1.00
- Resistance Level
- LPTX $0.36
- CANF $1.05
- Average True Range (ATR)
- LPTX 0.03
- CANF 0.02
- MACD
- LPTX 0.01
- CANF 0.00
- Stochastic Oscillator
- LPTX 86.94
- CANF 40.00
About LPTX Leap Therapeutics Inc.
Leap Therapeutics Inc is a biopharmaceutical company developing novel biomarker-targeted antibody therapies designed to treat patients with cancer by inhibiting fundamental tumor-promoting pathways, targeting cancer-specific cell surface molecules, and harnessing the immune system to attack cancer cells. The company's key clinical-stage drug candidate is sirexatamab (DKN-01), which targets Dickkopf-related protein 1 (DKK1) and is being studied in a clinical trial in patients with colorectal cancer. In addition, it also has a preclinical program to develop a proprietary monoclonal antibody, called FL-501 which works by inhibiting the GDF-15 protein.
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).